Licensing Vivitrex: A Win for the Mid-sized Pharma and Specialists

Cephalon's acquisition of US rights to Alkermes' Vivitrex, a long-acting formulation of the alcohol abuse drug naltrexone, is a clear sign that mid-sized companies with marketed products can--thanks to their significant cash flows--contend with Big Pharma for important specialist products.

Cephalon Inc. 's acquisition of US rights to Alkermes Inc. 's Vivitrex (long-acting formulation of the alcohol abuse drug naltrexone) is a clear sign that mid-sized companies with marketed products can—thanks to their significant cash flows—contend with Big Pharma for important specialist products [See Deal].

Not only did Cephalon convince Alkermes it could do as good or better a job marketing the product than a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Rising Leaders 2025: Regeneron’s Karen Rodriguez Lorenc On Not Believing In Failure

 
• By 

Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approval in Europe, now waiting for its US fate, she talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.